Literature DB >> 29967015

Pembrolizumab OK'd for Cervical Cancer.

.   

Abstract

The FDA approved the PD-1 inhibitor pembrolizumab as a second-line treatment for patients with recurrent or metastatic cervical cancer who expressed PD-L1 with a combined positive score of at least 1. The approval was based on results of a phase II trial in which patients treated with the drug had an objective response rate of 14.3%. ©2018 American Association for Cancer Research.

Entities:  

Year:  2018        PMID： 29967015     DOI： 10.1158/2159-8290.CD-NB2018-086

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  6 in total

Review 1.  The potential applications of T cell receptor (TCR)-like antibody in cervical cancer immunotherapy.

Authors:  Sylvia Annabel Dass; Rehasri Selva Rajan; Gee Jun Tye; Venugopal Balakrishnan
Journal:  Hum Vaccin Immunother       Date:  2021-05-14       Impact factor: 3.452

2.  Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels.

Authors:  A M Heeren; J Rotman; A G M Stam; N Pocorni; A A Gassama; S Samuels; M C G Bleeker; C H Mom; H J M A A Zijlmans; G G Kenter; E S Jordanova; T D de Gruijl
Journal:  J Immunother Cancer       Date:  2019-02-12       Impact factor: 13.751

Review 3.  Unlocking the therapeutic potential of primary tumor-draining lymph nodes.

Authors:  Jossie Rotman; Bas D Koster; Ekaterina S Jordanova; A Marijne Heeren; Tanja D de Gruijl
Journal:  Cancer Immunol Immunother       Date:  2019-04-03       Impact factor: 6.968

Review 4.  Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis.

Authors:  Tynisha S Rafael; Jossie Rotman; Oscar R Brouwer; Henk G van der Poel; Constantijne H Mom; Gemma G Kenter; Tanja D de Gruijl; Ekaterina S Jordanova
Journal:  J Clin Med       Date:  2022-02-19       Impact factor: 4.241

Review 5.  Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China.

Authors:  Takaaki Mizuno; Yuki Katsuya; Jun Sato; Takafumi Koyama; Toshio Shimizu; Noboru Yamamoto
Journal:  Front Oncol       Date:  2022-08-26       Impact factor: 5.738

Review 6.  Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade.

Authors:  Yu-Chen Chuang; Jen-Chih Tseng; Li-Rung Huang; Chun-Ming Huang; Chi-Ying F Huang; Tsung-Hsien Chuang
Journal:  Front Immunol       Date:  2020-05-29       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.